January month is the Thyroid awareness month, and it is a great way to comprehend the treatment, prevention, and causes of thyroid-related diseases and cancer for the people who are affected.
One of them is Thyroid eye disease, which is also known as Graves’ Orbitopathy or Ophthalmopathy that is an autoimmune disease. It occurs when the body’s immune system attacks the tissue surrounding the eye, causing inflammation in the tissues around and behind the eye.
DelveInsight Blog
Thyroid awareness month
Jan 28, 2020 | Reading Time: < 1 minute
Related Article
FDA Approves Xolair for Food Allergies; FDA Accelerated Approval for Iovance’s AMTAGVI; Astellas and Kelonia Enter into Research and License Agreement; Fast Track Designation to Certa’s FT011; Innovent Announces Phase 3 Clinical Trial Updates for IBI311; Orphan Drug Designation to Cardiol’s Pericarditis Drug Candidate
FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Roche has announced that the FDA has approved Xolair® (omalizumab) to mitigate allergic responses, such as anaphylaxis, that may arise from accidental exposure to various foods in both adult and pediatric patie...
Find MoreGraves’ Ophthalmopathy Treatment Market: A Billion-Dollar Opportunity For Pharma Companies
Graves’ ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves’ disease. The majority of Graves’ ophthalmopathy cases are caused due to Graves’ disease, and only a small percentage of these patients arise from other euthyr...
Find MoreIpsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL
Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.